Zymeworks (ZYME) Non-Current Assets (2021 - 2026)
Zymeworks (ZYME) reported Non-Current Assets of $92.5 million for Q1 2026, down 22.28% on a YoY basis from $119.1 million in Q1 2025, and down 5.34% sequentially from $97.8 million in Q4 2025.
Zymeworks (ZYME) Non-Current Assets (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Non-Current Assets data on file, last reported at $92.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 22.28% year-over-year to $92.5 million; the trailing twelve-month figure through Mar 2026 stood at $408.1 million (down 26.76% YoY), and the FY2025 full-year result was $97.8 million, down 39.89% from the prior year.
- Non-Current Assets retreated to $92.5 million in Q1 2026, from $97.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $181.7 million in Q3 2023 to a low of $92.5 million in Q1 2026.
- A 5-year average of $136.3 million and a median of $132.1 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets surged 65.8% in 2023 and tumbled 39.89% in 2025, its largest moves.
- Tracing ZYME's Non-Current Assets over 5 years: stood at $104.0 million in 2022, then soared by 61.46% to $168.0 million in 2023, then slipped by 3.16% to $162.6 million in 2024, then plunged by 39.89% to $97.8 million in 2025, then decreased by 5.34% to $92.5 million in 2026.
- Business Quant data shows ZYME's Non-Current Assets at $92.5 million in Q1 2026, $97.8 million in Q4 2025, and $105.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 92.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.54 Mn |
| Dec 31, 2025 | 97.76 Mn |
| Sep 30, 2025 | 105.56 Mn |
| Jun 30, 2025 | 112.26 Mn |
| Mar 31, 2025 | 119.06 Mn |
| Dec 31, 2024 | 162.64 Mn |
| Sep 30, 2024 | 143.38 Mn |
| Jun 30, 2024 | 132.14 Mn |
| Mar 31, 2024 | 159.93 Mn |
| Dec 31, 2023 | 167.95 Mn |
| Sep 30, 2023 | 181.73 Mn |
| Jun 30, 2023 | 181.72 Mn |
| Mar 31, 2023 | 174.37 Mn |
| Dec 31, 2022 | 104.02 Mn |
| Sep 30, 2022 | 109.61 Mn |
| Dec 31, 2021 | 100.91 Mn |